Get the Stockscreener App
3.44
0.00%
0.00
After Hours:
3.31
-0.13
-3.78%
Repare Therapeutics Inc stock is traded at $3.44, with a volume of 584.16K.
It is up +0.00% in the last 24 hours and up +18.21% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
See More
Previous Close:
$3.44
Open:
$3.45
24h Volume:
584.16K
Relative Volume:
5.18
Market Cap:
$141.98M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-22.93
EPS:
-0.15
Net Cash Flow:
$-129.10M
1W Performance:
+1.78%
1M Performance:
+18.21%
6M Performance:
-26.96%
1Y Performance:
-71.52%
1-Day Range:
$3.335
$3.47
1-Week Range:
$3.27
$3.58
52-Week Range:
$2.71
$12.16
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib - MarketWatch
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - StockTitan
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Bought by Blue Owl Capital Holdings LP - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Yahoo Finance
Replimune Group (NASDAQ:REPL) Stock Price Up 3.8% on Analyst Upgrade - MarketBeat
Financial Metrics Unveiled: Replimune Group Inc (REPL)’s Key Ratios in the Spotlight - The Dwinnex
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Public Employees Retirement Association of Colorado - Defense World
DNA Repair Drugs Market Freshly Published Findings Size, Key Manufacturers, Demand Analysis, Share And Over... - WhaTech
WORK Medical Technology Group LTD Ordinary Shares' Quiet Period Set To End on October 2nd (NASDAQ:WOK) - MarketBeat
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com India
A stock that deserves closer examination: Replimune Group Inc (REPL) - US Post News
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - StockTitan
Repare Therapeutics keeps Buy rating, stock target on updated trial results - Investing.com Canada
Repare Therapeutics reports key biomarkers linked to ovarian, endometrial cancer prognosis - Investing.com
Press Release Service: Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - CRISPR Medicine News
RPTXRepare Therapeutics Inc. Common Shares Latest Stock News & Market Updates - StockTitan
Repare Therapeutics' (RPTX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Repare Therapeutics (NASDAQ:RPTX) Receives Buy Rating from HC Wainwright - Defense World
Repare Therapeutics reports key biomarkers linked to ovarian, endometrial cancer prognosis - Investing.com India
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - StockTitan
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Analysts - Defense World
Biopharma Layoff Tracker 2024: AGC Biologics, Oncternal, Biosense Webster and More Cut Staff - BioSpace
Its Stock Has Paid Off Big Time For Replimune Group Inc - SETE News
Purple Biotech Reports Additional Positive Interim Data - GlobeNewswire
Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright - Defense World
Analytical Lens: Exploring Replimune Group Inc (REPL)’s Financial Story Through Ratios - The Dwinnex
Pixelworks (PXLW) and Universal Pictures Enter Agreement for TrueCut Motion Technology - StreetInsider.com
Replimune Group (NASDAQ:REPL) Stock Price Down 6.4% - MarketBeat
Repare Therapeutics Inc. (NASDAQ:RPTX) institutional owners may be pleased with recent gains after 68% loss over the past year - Simply Wall St
Acadian Asset Management LLC Acquires 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - MarketBeat
H.C. Wainwright maintains Buy rating on Replimune shares - Investing.com India
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study - Yahoo Finance
Acadian Asset Management LLC Purchases 284,036 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - StockTitan
Repare Therapeutics Inc. Forecasted to Post FY2024 Earnings of ($1.94) Per Share (NASDAQ:RPTX) - MarketBeat
Bloom Burton Comments on Repare Therapeutics Inc.’s FY2024 Earnings (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc. to Post FY2025 Earnings of ($2.79) Per Share, Bloom Burton Forecasts (NASDAQ:RPTX) - Defense World
Bloom Burton Weighs in on Repare Therapeutics Inc.'s FY2025 Earnings (NASDAQ:RPTX) - MarketBeat
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - StockTitan
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - StockTitan
Q3 2024 Earnings Estimate for Repare Therapeutics Inc. Issued By HC Wainwright (NASDAQ:RPTX) - Defense World
Repare Therapeutics Inc. to Post Q3 2024 Earnings of ($0.85) Per Share, HC Wainwright Forecasts (NASDAQ:RPTX) - MarketBeat
Repare Therapeutics divulges a novel strategy for BRCA-mutated tumors - BioWorld Online
Repare Therapeutics (NASDAQ:RPTX) Given Buy Rating at HC Wainwright - Defense World
Repare Therapeutics stock hits 52-week low at $2.76 - Investing.com
Repare Therapeutics' (RPTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Repare Therapeutics stock hits 52-week low at $2.76 By Investing.com - Investing.com UK
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data (RPTX) - Seeking Alpha
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada's Evolving Economic Landscape - MSN
Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - MedCity News
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):